PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 272 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,855,215 | -36.7% | 5,371,882 | +0.8% | 0.00% | -50.0% |
| Q2 2023 | $70,871,058 | +14.1% | 5,328,651 | -0.6% | 0.00% | 0.0% |
| Q1 2023 | $62,098,406 | -27.4% | 5,362,819 | -48.7% | 0.00% | +33.3% |
| Q4 2022 | $85,521,834 | +191.7% | 10,454,992 | +107.0% | 0.00% | +50.0% |
| Q3 2022 | $29,323,000 | +52.8% | 5,051,353 | +16.4% | 0.00% | +100.0% |
| Q2 2022 | $19,185,000 | -52.4% | 4,340,569 | -2.0% | 0.00% | -50.0% |
| Q1 2022 | $40,304,000 | -52.6% | 4,428,965 | +6.5% | 0.00% | -50.0% |
| Q4 2021 | $85,066,000 | -22.0% | 4,157,650 | -2.6% | 0.00% | -33.3% |
| Q3 2021 | $109,114,000 | -26.6% | 4,270,607 | +0.4% | 0.01% | -25.0% |
| Q2 2021 | $148,748,000 | +10.8% | 4,253,575 | +5.5% | 0.01% | 0.0% |
| Q1 2021 | $134,272,000 | +28.6% | 4,030,973 | +0.2% | 0.01% | +33.3% |
| Q4 2020 | $104,400,000 | +144.1% | 4,024,690 | -7.1% | 0.01% | +100.0% |
| Q3 2020 | $42,767,000 | +192.2% | 4,332,986 | +2.1% | 0.00% | +200.0% |
| Q2 2020 | $14,634,000 | +33.5% | 4,241,829 | +18.4% | 0.00% | 0.0% |
| Q1 2020 | $10,962,000 | -34.2% | 3,582,219 | +10.5% | 0.00% | 0.0% |
| Q4 2019 | $16,664,000 | +8.3% | 3,241,960 | +8.7% | 0.00% | 0.0% |
| Q3 2019 | $15,387,000 | -12.6% | 2,982,010 | +2.5% | 0.00% | 0.0% |
| Q2 2019 | $17,601,000 | -11.8% | 2,909,222 | +5.4% | 0.00% | -50.0% |
| Q1 2019 | $19,948,000 | +3.6% | 2,759,036 | +6.0% | 0.00% | 0.0% |
| Q4 2018 | $19,257,000 | +49.4% | 2,602,331 | +9.2% | 0.00% | +100.0% |
| Q3 2018 | $12,893,000 | +61.6% | 2,382,710 | +6.0% | 0.00% | 0.0% |
| Q2 2018 | $7,978,000 | +105.5% | 2,247,341 | +18.7% | 0.00% | – |
| Q1 2018 | $3,883,000 | -18.6% | 1,892,537 | +4.7% | 0.00% | – |
| Q4 2017 | $4,772,000 | -44.5% | 1,807,934 | +10.4% | 0.00% | -100.0% |
| Q3 2017 | $8,601,000 | +58.7% | 1,638,146 | +7.7% | 0.00% | – |
| Q2 2017 | $5,419,000 | -25.9% | 1,521,245 | +7.5% | 0.00% | -100.0% |
| Q1 2017 | $7,315,000 | +38.8% | 1,414,638 | +2.1% | 0.00% | – |
| Q4 2016 | $5,270,000 | -55.4% | 1,386,134 | +5.2% | 0.00% | -100.0% |
| Q3 2016 | $11,810,000 | +27.3% | 1,317,908 | -0.1% | 0.00% | 0.0% |
| Q2 2016 | $9,276,000 | +1.7% | 1,318,589 | +22.9% | 0.00% | 0.0% |
| Q1 2016 | $9,118,000 | -25.9% | 1,072,664 | +14.5% | 0.00% | 0.0% |
| Q4 2015 | $12,301,000 | +309.2% | 936,918 | +14.1% | 0.00% | – |
| Q3 2015 | $3,006,000 | -35.2% | 821,321 | +2.1% | 0.00% | – |
| Q2 2015 | $4,638,000 | -1.2% | 804,817 | +0.1% | 0.00% | – |
| Q1 2015 | $4,693,000 | -22.8% | 804,010 | +3.7% | 0.00% | -100.0% |
| Q4 2014 | $6,076,000 | +57.6% | 775,069 | -1.2% | 0.00% | – |
| Q3 2014 | $3,855,000 | -13.7% | 784,679 | +8.6% | 0.00% | – |
| Q2 2014 | $4,465,000 | +22.5% | 722,466 | +6.1% | 0.00% | – |
| Q1 2014 | $3,645,000 | -14.1% | 680,805 | -42.1% | 0.00% | – |
| Q4 2013 | $4,241,000 | +40.4% | 1,175,638 | +115.4% | 0.00% | – |
| Q3 2013 | $3,020,000 | +121.6% | 545,835 | +1.0% | 0.00% | – |
| Q2 2013 | $1,363,000 | – | 540,289 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |